Hepatitis Monthly

Published by: Kowsar

The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?

Alessio Strazzulla 1 , * , Rosa Maria Rita Iemmolo 2 , Ennio Carbone 3 , 4 , Maria Concetta Postorino 1 , Maria Mazzitelli 1 , Mario De Santis 5 , Fabrizio Di Benedetto 2 , Costanza Maria Cristiani 3 , Chiara Costa 1 , Vincenzo Pisani 1 and Carlo Torti 1
Authors Information
1 Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, “Magna Graecia” University, Catanzaro, Italy
2 Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, Italy
3 Experimental and Clinic Medicine, Department of Experimental and Clinical Medicine, “Magna Graecia” University, Catanzaro, Italy
4 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
5 Unit of Radiology, University of Modena and Reggio Emilia, Modena, Italy
Article information
  • Hepatitis Monthly: November 2016, 16 (11); e41933
  • Published Online: October 30, 2016
  • Article Type: Case Report
  • Received: August 31, 2016
  • Revised: October 7, 2016
  • Accepted: October 17, 2016
  • DOI: 10.5812/hepatmon.41933

To Cite: Strazzulla A, Maria Rita Iemmolo R, Carbone E, Concetta Postorino M, Mazzitelli M, et al. The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?, Hepat Mon. 2016 ;16(11):e41933. doi: 10.5812/hepatmon.41933.

Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016; 27(8): 1467-74[DOI][PubMed]
  • 2. Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol. 2016; [DOI][PubMed]
  • 3. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 2016; 65(4): 663-5[DOI][PubMed]
  • 4. Camma C, Cabibbo G, Craxi A. Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. J Hepatol. 2016; 65(4): 861-2[DOI][PubMed]
  • 5. Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 65(4): 741-7[DOI][PubMed]
  • 6. Reig M, Marino Z, Perello C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;
  • 7. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016; 65(4): 859-60[DOI][PubMed]
  • 8. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER CCACCC. Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohort. . J Hepatol. 2016;
  • 9. Fontana RJ, Brown RS, Moreno-Zamora A, Prieto M, Joshi S, Londono MC, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016; 22(4): 446-58[DOI][PubMed]
  • 10. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol. 2016; 65(4): 856-8[DOI][PubMed]
  • 11. Cardoso H, Vale AM, Rodrigues S, Goncalves R, Albuquerque A, Pereira P, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016; 65(5): 1070-1[DOI][PubMed]
  • 12. Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, Enooku K, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol. 2016; [DOI][PubMed]
  • 13. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016; 65(4): 727-33[DOI][PubMed]
  • 14. Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 2016; [DOI][PubMed]
  • 15. Llovet JM, Villanueva A. Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol. 2016; 13(10): 561-2[DOI][PubMed]
  • 16. Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015; 21(2): 105-14[DOI][PubMed]
  • 17. Hengst J, Strunz B, Deterding K, Ljunggren HG, Leeansyah E, Manns MP, et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur J Immunol. 2016; 46(9): 2204-10[DOI][PubMed]
  • 18. Serti E, Park H, Keane M, O'Keefe AC, Rivera E, Liang TJ, et al. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNalpha. Gut. 2016; [DOI][PubMed]
  • 19. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4): 908-43[DOI][PubMed]
  • 20. Walker NF, Scriven J, Meintjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl). 2015; 7: 49-64[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader